Ikena Oncology Inc Stock price
Is Ikena Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Ikena Oncology Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Ikena Oncology Inc forecast:
Analyst Opinions
8 Analysts have issued a Ikena Oncology Inc forecast:
Don't miss a Thing! We will send you all news about Ikena Oncology Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Dr. Manfredi |
| Employees | 9 |
| Founded | 2016 |
| Website | www.ikenaoncology.com |


